[go: up one dir, main page]

EP1315965A4 - Procedes et compositions utilises pour le ciblage in vitro - Google Patents

Procedes et compositions utilises pour le ciblage in vitro

Info

Publication number
EP1315965A4
EP1315965A4 EP01970671A EP01970671A EP1315965A4 EP 1315965 A4 EP1315965 A4 EP 1315965A4 EP 01970671 A EP01970671 A EP 01970671A EP 01970671 A EP01970671 A EP 01970671A EP 1315965 A4 EP1315965 A4 EP 1315965A4
Authority
EP
European Patent Office
Prior art keywords
disclosed
methods
peptides
novel
targeting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01970671A
Other languages
German (de)
English (en)
Other versions
EP1315965A2 (fr
Inventor
Wadih Arap
Renata Pasqualini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
University of Texas at Austin
Original Assignee
University of Texas System
University of Texas at Austin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System, University of Texas at Austin filed Critical University of Texas System
Publication of EP1315965A2 publication Critical patent/EP1315965A2/fr
Publication of EP1315965A4 publication Critical patent/EP1315965A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
EP01970671A 2000-09-08 2001-09-07 Procedes et compositions utilises pour le ciblage in vitro Withdrawn EP1315965A4 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US23126600P 2000-09-08 2000-09-08
US231266P 2000-09-08
US76510101A 2001-01-17 2001-01-17
US765101 2001-01-17
PCT/US2001/027702 WO2002020722A2 (fr) 2000-09-08 2001-09-07 Procedes et compositions utilises pour le ciblage in vitro

Publications (2)

Publication Number Publication Date
EP1315965A2 EP1315965A2 (fr) 2003-06-04
EP1315965A4 true EP1315965A4 (fr) 2006-04-05

Family

ID=26924954

Family Applications (6)

Application Number Title Priority Date Filing Date
EP01970681A Withdrawn EP1315830A4 (fr) 2000-09-08 2001-09-07 Compositions et procedes se rapporant a des peptides ciblants chez l'homme in vivo
EP01970671A Withdrawn EP1315965A4 (fr) 2000-09-08 2001-09-07 Procedes et compositions utilises pour le ciblage in vitro
EP01968603A Expired - Lifetime EP1322755B1 (fr) 2000-09-08 2001-09-07 Peptides de ciblage humains et murins identifies par expression phagique
EP01970682A Withdrawn EP1315512A4 (fr) 2000-09-08 2001-09-07 Ciblage ad noviral et manipulation de la r ponse du syst me immunitaire au moyen de peptides ciblants
EP01968683A Withdrawn EP1315840A4 (fr) 2000-09-08 2001-09-07 Biopanning et analyse rapide de ligands interactifs selectifs (brasil)
EP08016646A Withdrawn EP2028187A1 (fr) 2000-09-08 2001-09-07 Peptides cibles chez l'homme et la souris identifiées par l'affichage de phases

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP01970681A Withdrawn EP1315830A4 (fr) 2000-09-08 2001-09-07 Compositions et procedes se rapporant a des peptides ciblants chez l'homme in vivo

Family Applications After (4)

Application Number Title Priority Date Filing Date
EP01968603A Expired - Lifetime EP1322755B1 (fr) 2000-09-08 2001-09-07 Peptides de ciblage humains et murins identifies par expression phagique
EP01970682A Withdrawn EP1315512A4 (fr) 2000-09-08 2001-09-07 Ciblage ad noviral et manipulation de la r ponse du syst me immunitaire au moyen de peptides ciblants
EP01968683A Withdrawn EP1315840A4 (fr) 2000-09-08 2001-09-07 Biopanning et analyse rapide de ligands interactifs selectifs (brasil)
EP08016646A Withdrawn EP2028187A1 (fr) 2000-09-08 2001-09-07 Peptides cibles chez l'homme et la souris identifiées par l'affichage de phases

Country Status (7)

Country Link
EP (6) EP1315830A4 (fr)
JP (6) JP2004533803A (fr)
AT (1) ATE478141T1 (fr)
CA (5) CA2421191A1 (fr)
DE (1) DE60142840D1 (fr)
PT (1) PT1322755E (fr)
WO (4) WO2002020723A2 (fr)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4603157B2 (ja) * 1998-03-13 2010-12-22 ザ バーナム インスティチュート 種々の選択された器官または組織にホーミングする分子
US7420030B2 (en) 2000-09-08 2008-09-02 The Board Of Regents Of The University Of Texas System Aminopeptidase A (APA) targeting peptides for the treatment of cancer
US20040170955A1 (en) 2000-09-08 2004-09-02 Wadih Arap Human and mouse targeting peptides identified by phage display
JP5077862B2 (ja) * 2000-09-08 2012-11-21 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム ファージディスプレイにより同定されたヒト及びマウスのターゲティングペプチド
US7452964B2 (en) 2001-09-07 2008-11-18 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides against placenta and adipose tissues
US7671010B2 (en) 2002-08-30 2010-03-02 The Board Of Regents Of The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
US8507445B2 (en) 2001-09-07 2013-08-13 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
US7371719B2 (en) 2002-02-15 2008-05-13 Northwestern University Self-assembly of peptide-amphiphile nanofibers under physiological conditions
EP1346729A1 (fr) * 2002-03-19 2003-09-24 Cardiovascular Research Institute Maastricht Cibler l'angiogénèse du myocarde à l'aide de CD13/APN
WO2003106640A2 (fr) 2002-06-14 2003-12-24 Case Western Reserve University Procedes et compositions de ciblage cellulaire
AU2002364501A1 (en) * 2002-08-30 2004-03-19 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
US7554021B2 (en) 2002-11-12 2009-06-30 Northwestern University Composition and method for self-assembly and mineralization of peptide amphiphiles
WO2004084950A2 (fr) * 2003-03-24 2004-10-07 Case Western Reserve University Procedes et compositions de ciblage cellulaire
NZ564694A (en) * 2003-04-22 2009-11-27 Sod Conseils Rech Applic Peptide vectors
US20040248109A1 (en) * 2003-06-09 2004-12-09 Lawrence Greenfield Methods for selecting protein binding moieties
US20050187161A1 (en) * 2003-09-12 2005-08-25 Board Of Regents, The University Of Texas System Biopanning as an approach to study the pathogenesis of and produce novel treatment modalities for invasive Aspergillosis
JP4870348B2 (ja) * 2003-12-04 2012-02-08 株式会社ペルセウスプロテオミクス 細胞表面抗原に対する抗体取得とその抗原同定
JP2011239784A (ja) * 2003-12-04 2011-12-01 Perseus Proteomics Inc 細胞表面抗原に対する抗体取得とその抗原同定
CN1905892A (zh) 2003-12-05 2007-01-31 西北大学 自组装的肽两亲物和用于生长因子传递的相关方法
US8377484B1 (en) * 2004-05-06 2013-02-19 Maria V. Tsiper Tumor encapsulation for prevention and treatment of metastatic cancer disease
CN1294418C (zh) * 2004-08-09 2007-01-10 中国人民解放军南京军区南京总医院 检测白念珠菌菌丝蛋白抗体的方法及试剂盒
GB0422431D0 (en) * 2004-10-08 2004-11-10 Affitech As Method
ITRM20040568A1 (it) * 2004-11-18 2005-02-18 Uni Degli Studi Di Roma Tor Vergata Uso della tecnica "phage display" per l'identificazione di peptidi con capacita' di legame a cellule staminali/progenitore, peptidi cosi' ottenuti e loro usi.
US20090180958A1 (en) * 2005-04-26 2009-07-16 Karyon-Ctt Ltd. Diagnostic and therapeutic agents
ES2397441T5 (es) 2006-02-13 2022-09-14 Daiichi Sankyo Co Ltd Secuencias polinucleotídicas y polipeptídicas implicadas en el proceso de remodelación ósea
US8168181B2 (en) 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
EP2338898A1 (fr) * 2006-03-09 2011-06-29 The Board of Regents of the University of Texas System Compositions et procédé liés au profilage d'une pluralité de lignées cellulaires basé sur la liaison de peptides
WO2008105560A1 (fr) * 2007-02-27 2008-09-04 Forerunner Pharma Research Co., Ltd. Composition pharmaceutique comportant un anticorps anti-grp 78 en tant qu'ingrédient actif
US8076295B2 (en) 2007-04-17 2011-12-13 Nanotope, Inc. Peptide amphiphiles having improved solubility and methods of using same
WO2009036167A1 (fr) * 2007-09-14 2009-03-19 Vanderbilt University Ciblage d'une fonction de récepteurs notch3 pour une thérapie du cancer
EP3543256A1 (fr) * 2009-01-12 2019-09-25 Cytomx Therapeutics Inc. Compositions d anticorps modifiées et leurs procédés de production et d'utilisation
AU2010236584A1 (en) 2009-04-13 2011-11-10 Northwestern University Novel peptide-based scaffolds for cartilage regeneration and methods for their use
CA2827029C (fr) 2011-02-11 2019-07-02 The Regents Of The University Of Michigan Compositions peptidiques et procedes de traitement de patients
JP6336400B2 (ja) * 2012-02-10 2018-06-06 フィロジカ リミテッドＰｈｙｌｏｇｉｃａ Ｌｉｍｉｔｅｄ 標的タンパク質上の相互作用部位を特性決定する方法
WO2013149237A1 (fr) * 2012-03-30 2013-10-03 Board Of Regents, The University Of Texas System Ciblage intracellulaire de signaux de localisation spécifique pour des organites avec des ligands fonctionnels autoguidés dérivés de bibliothèques combinatoires de phages d'internalisation dans des cellules
US9493562B2 (en) 2012-07-19 2016-11-15 Alethia Biotherapeutics Inc. Anti-Siglec-15 antibodies
GB201308745D0 (en) * 2013-05-15 2013-06-26 Imp Innovations Bacteriophage
CN103497236B (zh) * 2013-09-25 2017-05-10 浙江省医学科学院 靶向wisp‑1蛋白的特异性七肽及其应用
GB2522412A (en) * 2014-01-22 2015-07-29 Agency Science Tech & Res Antimicrobial peptidomimetics
KR20160122161A (ko) 2014-02-19 2016-10-21 에프. 호프만-라 로슈 아게 혈액 뇌 장벽 셔틀
US10799568B2 (en) * 2014-05-19 2020-10-13 Valo Therapeutics Oy Modified adenoviruses for cancer vaccines development
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
CN105769909A (zh) * 2016-05-13 2016-07-20 云南舜喜再生医学工程有限公司 一种直接获得富含细胞因子血清的采血器及方法
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
KR101921836B1 (ko) 2017-11-23 2018-11-26 서울대학교병원 피부성체 줄기세포의 분화 조절 방법, 및 피부성체 줄기세포의 분화 조절용 조성물 및 키트
WO2020068815A1 (fr) * 2018-09-25 2020-04-02 Emory University Acides nucléiques pour la reconnaissance et l'intégration de cellules
CN109137086A (zh) * 2018-10-16 2019-01-04 梁耀极 一种改良的全长mRNA测序的建库方法
BR102019014302A2 (pt) 2019-07-10 2021-12-28 Universidade Federal de Uberlândia Peptídeos recombinantes ligantes ao anticorpo tumoral específico para cancer de mama e uso
EP3767628B1 (fr) 2019-07-18 2024-03-27 Bayer Aktiengesellschaft Sélection d'anticorps / de fragments d'anticorps
EP4076658A1 (fr) * 2019-12-17 2022-10-26 Mie University Procédés et compositions pour évaluer et traiter une fibrose
KR102749110B1 (ko) * 2021-11-04 2025-01-03 (주)케어젠 생리 활성을 갖는 펩타이드 및 그의 용도
GB202211043D0 (en) * 2022-07-28 2022-09-14 Univ Birmingham Peptide agonist

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999046284A2 (fr) * 1998-03-13 1999-09-16 The Burnham Institute Molecules se logeant dans divers organes ou tissus

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4957939A (en) 1981-07-24 1990-09-18 Schering Aktiengesellschaft Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging
US4472509A (en) 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
US5206347A (en) 1985-08-06 1993-04-27 La Jolla Cancer Research Foundation Isolation and use of receptors binding to a peptide column
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5252296A (en) 1990-05-15 1993-10-12 Chiron Corporation Method and apparatus for biopolymer synthesis
ATE132367T1 (de) 1991-02-14 1996-01-15 Baxter Int Bindung substratspezifischer affinitätssubstanzen an liposomen
US5603872A (en) 1991-02-14 1997-02-18 Baxter International Inc. Method of binding recognizing substances to liposomes
US5329028A (en) 1992-08-05 1994-07-12 Genentech, Inc. Carbohydrate-directed cross-linking reagents
WO1994028424A1 (fr) * 1993-05-28 1994-12-08 Chiron Corporation Procede de selection de sequences de peptides biologiquement actifs
US5492807A (en) 1993-11-19 1996-02-20 Santi; Daniel V. Method of obtaining diagnostic reagents, assays and therapeutics based on clinical manifestations of a disease
US5622699A (en) 1995-09-11 1997-04-22 La Jolla Cancer Research Foundation Method of identifying molecules that home to a selected organ in vivo
DE69637395T2 (de) * 1995-09-11 2008-12-18 La Jolla Cancer Research Foundation, La Jolla Moleküle, die sich in ausgewählten Organen oder Geweben in-vivo einfinden
US6068829A (en) 1995-09-11 2000-05-30 The Burnham Institute Method of identifying molecules that home to a selected organ in vivo
WO2000014215A1 (fr) * 1998-09-07 2000-03-16 Eberhard-Karls-Universität Tübingen Procede de selection de peptides pour le transport cible de medicaments et de marqueurs et peptides decouverts a l'aide dudit procede

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999046284A2 (fr) * 1998-03-13 1999-09-16 The Burnham Institute Molecules se logeant dans divers organes ou tissus

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ARAP MARCO A ET AL: "Cell surface expression of the stress response chaperone GRP78 enables tumor targeting by circulating ligands", CANCER CELL, vol. 6, no. 3, September 2004 (2004-09-01), pages 275 - 284, XP002366633, ISSN: 1535-6108 *
ARAP WADIH ET AL: "Targeting the prostate for destruction through a vascular address", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 99, no. 3, 5 February 2002 (2002-02-05), pages 1527 - 1531, XP002366602, ISSN: 0027-8424 *
CHINNI S R ET AL: "Humoral immune responses to cathepsin D and glucose-regulated protein 78 in ovarian cancer patients.", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. SEP 1997, vol. 3, no. 9, September 1997 (1997-09-01), pages 1557 - 1564, XP002366776, ISSN: 1078-0432 *
FURUYA Y ET AL: "THE ROLE OF CALCIUM, PH, AND CELL PROLIFERATION IN THE PROGRAMMED (APOPTOTIC) DEATH OF ANDROGEN-INDEPENDENT PROSTATIC CANCER CELLS INDUCED BY THAPSIGARGIN", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 54, no. 23, December 1994 (1994-12-01), pages 6167 - 6175, XP000892128, ISSN: 0008-5472 *
GONG M C ET AL: "Prostate-specific membrane antigen (PMSA)-specific monoclonal antibodies in the treatment of prostate and other cancers", CANCER AND METASTASIS REVIEWS, KLUWER ACADEMIC PUBLISHERS, DORDRECHT, NL, vol. 18, no. 4, 1999, pages 483 - 490, XP002982445, ISSN: 0167-7659 *
MINTZ PAUL J ET AL: "Fingerprinting the circulating repertoire of antibodies from cancer patients.", NATURE BIOTECHNOLOGY, vol. 21, no. 1, January 2003 (2003-01-01), pages 57 - 63, XP002366632, ISSN: 1087-0156 *
NICKLIN S A ET AL: "Selective targeting of gene transfer to vascular endothelial cells by use of peptides isolated by phage display.", CIRCULATION. 11 JUL 2000, vol. 102, no. 2, 11 July 2000 (2000-07-11), pages 231 - 237, XP002327757, ISSN: 1524-4539 *

Also Published As

Publication number Publication date
JP2004530404A (ja) 2004-10-07
CA2421271A1 (fr) 2002-03-14
EP1315840A4 (fr) 2005-11-02
JP2004533803A (ja) 2004-11-11
WO2002020724A2 (fr) 2002-03-14
WO2002020723A3 (fr) 2002-08-29
EP1315512A4 (fr) 2005-11-09
ATE478141T1 (de) 2010-09-15
EP1322755B1 (fr) 2010-08-18
PT1322755E (pt) 2010-11-19
EP1315830A2 (fr) 2003-06-04
EP1315830A4 (fr) 2005-10-19
CA2421380A1 (fr) 2002-03-14
CA2421200A1 (fr) 2002-03-14
EP1315965A2 (fr) 2003-06-04
WO2002020722A3 (fr) 2003-02-06
JP2011120587A (ja) 2011-06-23
JP2004515751A (ja) 2004-05-27
DE60142840D1 (de) 2010-09-30
WO2002020822A2 (fr) 2002-03-14
EP1322755A4 (fr) 2006-04-05
WO2002020722A9 (fr) 2003-08-21
WO2002020724A3 (fr) 2002-07-11
WO2002020722A2 (fr) 2002-03-14
WO2002020723A2 (fr) 2002-03-14
CA2421195A1 (fr) 2002-03-14
EP1322755A1 (fr) 2003-07-02
EP1315512A2 (fr) 2003-06-04
JP2012065662A (ja) 2012-04-05
JP5591209B2 (ja) 2014-09-17
JP2004536020A (ja) 2004-12-02
CA2421191A1 (fr) 2002-03-14
EP2028187A1 (fr) 2009-02-25
WO2002020822A3 (fr) 2002-06-27
EP1315840A2 (fr) 2003-06-04

Similar Documents

Publication Publication Date Title
EP1315965A4 (fr) Procedes et compositions utilises pour le ciblage in vitro
ES2629086T3 (es) Sustancia farmacéutica para promover la regeneración funcional de tejido dañado
WO2001051604A3 (fr) Procedes d'identification de cibles de medicaments anticancereux
CY1121447T1 (el) Συνθεσεις για αυξηση δραστηριοτητας τελομερασης
ES2107041T3 (es) Variantes de activador de plasminogeno tisular obtenidos por glicosilacion, que presentan propiedades terapeuticas.
CY1107351T1 (el) Καινοφανης μεταλλαγμενη μορφη απιμινασης αργινινης
ATE340560T1 (de) Verfahren und zusammensetzungen für nichtvirale gentherapie zur behandlung von hyperproliferativen krankheiten
DE60018920D1 (de) Rekombinante adenovirale vektoren, die chimäre fiberproteine exprimieren, für die zellspezifische infektion und genomische integration
EP1100535A4 (fr) Ciblage d'agents pharmaceutiques sur des tissus blesses
ATE253586T1 (de) 2-(purin-9-yl)-tetrahydrofuran-3,4-diol-derivat
SG158919A1 (en) Constructs binding to phosphatidylserine and their use in disease treatment
PT1062321E (pt) Utilizacoes para celulas estaminais mesenquimais humanas nao autologas
DK1677833T3 (da) Virusvektor til anvendelse til in vivo-genterapi af Parkinsons sygdom
WO2002032292A3 (fr) Procedes pour la mise au point et l'utilisation d'agents diagnostiques et therapeutiques
EP1446162A4 (fr) Oligonucleotides immunostimulateurs a motif combine possedant une activite accrue
ATE355374T1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
DE60122304D1 (de) Auf lipiden basierendes system zur zielgerichteten verabreichung diagnostischer wirkstoffe
DE69527049D1 (de) Therapeutische verwendungen von bakterizide/permeabilitätserhöhende protein dimer produkte
ATE228016T1 (de) Lebendvakzine zur behandlung von tumorerkrankungen
BRPI0510206A (pt) método de identificação de fenótipo, célula isolada, métodos de identificação de agentes, agentes, agentes terapêuticos, método de avaliação de agente terapêutico, composição farmacêutica, métodos de tratamento, prevenção ou melhoria de disfunções e métodos de modulação
ATE287958T1 (de) Verbesserte krebstherapie
ATE423574T1 (de) Dominant-negativer plb mutant zur behandlung der herzerkrankungen
DE60129069D1 (de) Hepatitis B Virus Vektoren für Gentherapie
EA200000828A1 (ru) Терапия ангиогенеза с помощью переноса генов и способы внутрисосудистой доставки генов
AU6987696A (en) The use of the wap of mmtv regulatory sequences for targeted expression of linked heterologous genes in human mammary cells, including human mammary carcinoma cells

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030306

AK Designated contracting states

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

A4 Supplementary search report drawn up and despatched

Effective date: 20060220

17Q First examination report despatched

Effective date: 20060810

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20070221